In this section

Clinical Photonics

We use light to develop advanced diagnostic tools, wearable sensors, and microscale robots for studying diseases and enabling minimally invasive treatments.

Head of Group

Dr Alex Thompson

Office B411, Bessemer Building,
South Kensington Campus

⇒ X @_Thompson_Alex

What we do

We use photonics to develop new technologies for medicine and to study the pathophysiology of disease. This includes new and improved diagnostic tools as well as microscale robotic devices for therapeutic applications. We use a variety of optical techniques for this purpose such as fluorescence, Raman and diffuse reflectance spectroscopy, as well as microscopy and interferometry. We develop devices ranging from wearable sensors and fibre-optic probes for minimally invasive diagnostics through to microscale robots for cellular-scale manipulation and therapy.

Why it is important?

Our research has a number of potential clinical applications including improved monitoring of clinical therapies and interventions (e.g. in inflammatory bowel disease and malnutrition), early diagnosis of infection, and even margin mapping in tumour resection surgery.

How can it benefit patients?

The devices we are developing can potentially provide less invasive and lower cost diagnostics. In turn, this may facilitate patient benefits including earlier diagnosis, earlier identification of relapse (e.g. in therapy response monitoring applications), more widespread deployment and more comfortable patient experiences (e.g. through use of less invasive probes and sensors).

Meet the team

No results found

Showing results for:
Reset all filters

Conference paper
McHutchison JG, Thompson AJ, Jacobson IM, Boyer TD, Schiff ER, Everson GT, Vierling JM, Shiffman ML, Brown RS, Di Bisceglie AM, Gordon SC, Lee WM, Guo Z, King TH, Armstrong B, Rodell TC, Apelian Det al., 2010,
PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL <i>IL</i>-<i>28</i>B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN
, 45th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Publisher: ELSEVIER SCIENCE BV, Pages: S457-S457, ISSN: 0168-8278
- Cite
Conference paper
Thompson AJ, Chang JJ, Skinner NA, Lewin S, Visvanathan K, Desmond PV, Locarnini Set al., 2008,
INCREASED INNATE AND ADAPTIVE IMMUNE PRESSURE IS RESPONSIBLE FOR THE REDUCED TRANSCRIPTIONAL ACTIVITY OF INTRAHEPATIC COVALENTLY CLOSED CIRCULAR (CCC) DNA THAT OCCURS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB)
, 59th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: JOHN WILEY & SONS INC, Pages: 675A-675A, ISSN: 0270-9139
- Cite
Conference paper
Thompson AJ, Preiss S, Chen X, Revill P, Desmond P, Visvanathan K, Locarnini Set al., 2006,
Stimulation of the interleukin-1-receptor and toll-like receptor-2 inhibits hepatitis B virus replication in hepatoma cell-lines
, 57th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases, Publisher: JOHN WILEY & SONS INC, Pages: 537A-537A, ISSN: 0270-9139
- Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://www.imperial.ac.uk:80/respub/WEB-INF/jsp/search-t4-html.jsp Request URI: /respub/WEB-INF/jsp/search-t4-html.jsp Query String: id=1308&limit=10&page=7&respub-action=search.html Current Millis: 1730424437627 Current Time: Fri Nov 01 01:27:17 GMT 2024